Ischemia-reperfusion injury MedDRA version: 9.1 Level: LLT Classification code 10023034 Term: Ischemia peripheral
Conditions
Interventions
Trade Name: Crestor
Product Name: Rosuvastatin
Pharmaceutical Form: Capsule*
CAS Number: 287714414
Other descriptive name: Rosuvastatin
Concentration unit: mg milligram(s)
Concentration type: equal
Co
Sponsors
Dept. Pharmacology and Toxicology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age between 18 and 50 years Signed infomed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Hypertension (systole > 140 mmHg, diastole > 90 mmHg) Hypercholesterolemia (fasting total cholesterol > 6.0 mmol/l) Diabetes mellitus (fasting glucose > 7.0 mmol/l, random glucose > 11.0 mmol/l) Alanine amino transferase > 90 U/l (twice the upper level of normal range) Creatinine Kinase > 440 U/l (twice the upper level of normal range) Cardiovascular disease Participation in any clinical trial in the last 60 days Concomitant medication use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine whether a one-week treatment with rosuvastatin augments dipyridamole-induced forearm vasodilation by increased adenosine receptor stimulation. ;Secondary Objective: To determine whether a one-week treatment with rosuvastatin increases adenosine formation. To determine whether a one-week treatment with rosuvastatin increases reactive hyperemia. ;Primary end point(s): 1) Forearm vasodilatory response (forearm blood flow) to intra-arterial dipyridamole infusion with and without concomitant caffeine administration | — |
Countries
Netherlands
Outcome results
None listed